SecBot SecBot
144 ·Filed Sep 15, 2026

DNA

Ginkgo Bioworks Holdings, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed2mo ago SEC0001959173-26-006973
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

No actionable signal. This is a routine, small-dollar director sale of vested RSUs. Monitor for any larger insider sales or changes in insider filing patterns ahead of next earnings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$6.99
T+0 close · Sep 15, 2026 · via day close
Latest settled
+68.24%
T+20 · $11.76 · next T+60 in 22d
Vs SPY
+65.26%
α at T+20
Latest observation
+55.33%
T+43 · FF3 residual α
  1. T+0 · Sep 15 $6.99entry
  2. T+1 · 2mo ago +4.01%α +3.68% · $7.27
  3. T+5 · 8w ago +12.73%α +11.91% · $7.88
  4. T+20 · 5w ago +68.24%α +65.26% · $11.76
  5. T+44 · todayOpen
  6. T+60 · in 22d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Christian O. Henry filed a Form 144 notice to sell 5,000 Class A shares (~$35,406 at ~$7.08/sh), representing a routine, small-dollar sale by a director. The shares were acquired via restricted stock vesting from 2022-2023. Given the minimal size relative to market cap ($451M) and the director's role (not CEO/CFO), this filing is routine and carries no material signal.

Key Facts

  • Director Christian O. Henry filed Form 144 to sell 5,000 Class A shares.
  • Estimated proceeds: ~$35,406 based on filing date price.
  • Shares were acquired through restricted stock vesting from March 2022 to April 2023.
  • Sale represents a small fraction of director's holdings and company market cap ($451M).

Financial Impact

~$35,406 sale by a director, immaterial relative to $451M market cap.

Risk Factors

  • Form 144 is an intent to sell, the sale may not be executed.
  • No material risk to equity value from this filing.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-006973
Document: 0001959173-26-006973-index.html0001959173-26-006973
Document: 0001959173-26-006973.txt0001959173-26-006973

Track record

7 reports on DNA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $11.29 Now $8.50 −24.71% settles Feb 4
  2. Oct 29, 202618d ago 8-K Neutral 2/10 Entry $11.21 Now $8.50 −24.17% settles Jan 28
  3. Oct 21, 202626d ago Insider Cluster Neutral 2/10 Entry $9.71 Now $8.50 −12.46% settles Jan 20
  4. Oct 19, 202628d ago 144 Neutral 2/10 Entry $10.07 Now $8.50 −15.59% settles Jan 14
  5. Sep 15, 20268w ago 144 Neutral 2/10 Viewing Entry $6.99 Now $8.50 +21.60% settles Dec 9
  6. Apr 9, 202631w ago Insider Cluster Bearish 6/10 Entry $6.43 to $10.11 Now $8.50 −32.19% ▼ −57.23% −46.45% vs SPY
  7. Apr 9, 202631w ago Insider Cluster Bearish 6/10 Entry $6.43 to $10.11 Now $8.50 −32.19% ▼ −57.23% −46.45% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 15, 2026